Niagen Bioscience Inc Revenue Growth Rates (NAGE), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Niagen Bioscience Inc   (NASDAQ: NAGE)
 

NAGE's Revenue Growth by Quarter and Year

Niagen Bioscience Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NAGE/growth
https://api.csimarket.com/api/v1/companies/NAGE/fundamentals
https://api.csimarket.com/api/v1/companies/NAGE/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
NAGE Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 27.19
2nd Quarter June 29.79
1st Quarter March 31.47
FY 88.45

NAGEs Annual Revenue
Niagen Bioscience Inc 's Revenue in the fiscal year 2025 $ 129.42 millions
Niagen Bioscience Inc 's Revenue in the fiscal year 2024 $ 99.60 millions
Niagen Bioscience Inc 's Revenue in the fiscal year 2023 $ 83.57 millions
Niagen Bioscience Inc 's Revenue in the fiscal year 2022 $ 72.05 millions
Niagen Bioscience Inc 's Revenue in the fiscal year 2021 $ 67.45 millions




NAGE Revenue third quarter 2026 Y/Y Growth Comment
Niagen Bioscience Inc reported decline in Revenue in the third quarter 2026 by -20% to $ 27.19 millions, from the same quarter in 2025.
The contraction in the third quarter 2026 Niagen Bioscience Inc 's Revenue compares unfavorably to the Company's average Revenue rise of 23.79%.

Looking into third quarter 2026 results within Legal Cannabis industry 8 other companies have achieved higher Revenue growth. While Niagen Bioscience Inc ' s Revenue fall of -20% ranks overall at the positon no. 1718 in the third quarter 2026.


NAGE Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -20 %
2nd Quarter June -4.27 %
1st Quarter March 3.25 %
FY   -

Financial Statements
Niagen Bioscience Inc 's third quarter 2026 Revenue $ 27.19 millions NAGE's Income Statement
Niagen Bioscience Inc 's third quarter 2025 Revenue $ 33.99 millions Quarterly NAGE's Income Statement


NAGE Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -8.72 %
2nd Quarter June -5.34 %
1st Quarter March -7 %
FY (Year on Year)   -


Back to NAGE Growth rate Comparisons >> Back to NAGE Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry #9
Consumer Non Cyclical Sector #54
Overall #1718

Revenue Y/Y Growth Statistics
High Average Low
63.86 % 23.79 % -23.9 %
(Jul 04 2015)   (Jul 01 2017)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry #9
Consumer Non Cyclical Sector #54
Overall #1718
Revenue Y/Y Growth Statistics
High Average Low
63.86 % 23.79 % -23.9 %
(Jul 04 2015)   (Jul 01 2017)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Niagen Bioscience Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
67.99 % 5.45 % -43.29 %
(Apr 02 2016)  


NAGE's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Niagen Bioscience Inc disclosed drop in Revenue from the second quarter by -8.72% to $ 27.19 millions, from $ 29.79 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Legal Cannabis's company achievement, Most analysts pointed out.

Within Legal Cannabis industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Niagen Bioscience Inc 's Revenue growth quarter on quarter, overall rank is 2493.


Revenue Q/Q Growth Company Ranking
Within: No.
Legal Cannabis Industry #12
Consumer Non Cyclical Sector #89
Overall #2493
Revenue Q/Q Growth Company Ranking
Within: No.
Legal Cannabis Industry #12
Consumer Non Cyclical Sector #89
Overall #2493
Revenue Q/Q Growth Statistics
High Average Low
67.99 % 5.45 % -43.29 %
(Apr 02 2016)  


NAGE's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Niagen Bioscience Inc disclosed drop in Revenue from the second quarter by -8.72% to $ 27.19 millions, from $ 29.79 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Legal Cannabis's company achievement, Most analysts pointed out.

Within Legal Cannabis industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Niagen Bioscience Inc 's Revenue growth quarter on quarter, overall rank is 2493.


Niagen Bioscience Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 129.08
Y / Y Revenue Growth (TTM) 10.99 %
Year on Year Revenue Growth Overall Ranking # 462
Seqeuential Revenue Change (TTM) -1.02 %
Seq. Revenue Growth (TTM) Overall Ranking # 1718


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Niagen Bioscience Inc 's cumulative twelve months Revenue were $ 129 millions, company would post below average annual Revenue growth of -1.02% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Niagen Bioscience Inc 's Revenue growth from the 29.79% growth in Mar 31 2026.

Among companies within the Consumer Non Cyclical sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 442 to 462.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry # 9
Consumer Non Cyclical Sector # 20
Overall # 462

Revenue TTM Y/Y Growth Statistics
High Average Low
63.86 %
 23.79 %
-23.9 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 54
S&P 500 # 1718
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Niagen Bioscience Inc 's cumulative twelve months Revenue were $ 129 millions, company would post below average annual Revenue growth of -23.9% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Niagen Bioscience Inc 's Revenue growth from the 29.79% growth in Mar 31 2026.

Among companies within the Consumer Non Cyclical sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 442 to 462.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry # 9
Consumer Non Cyclical Sector # 20
Overall # 462

Revenue TTM Y/Y Growth Statistics
High Average Low
63.86 %
23.79 %
-23.9 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 54
S&P 500 # 1718




Other Revenue Growth
Legal Cannabis Industry Revenue Growth Trends and Statistics
Consumer Non Cyclical Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NAGE's Revenue Growth Ratio versus Legal Cannabis Industry, Consumer Non Cyclical Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Consumer Non Cyclical SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Ingredion Incorporated-1.32%$ -1.322 millions
Coty Inc -1.37%$ -1.370 millions
Tootsie Roll Industries Inc-1.44%$ -1.440 millions
Kraft Heinz Co-1.96%$ -1.956 millions
Utz Brands Inc -2.04%$ -2.043 millions
Pilgrim s Pride Corporation-2.21%$ -2.210 millions
The Marzetti Company-2.29%$ -2.292 millions
The Boston Beer Company Inc -3.24%$ -3.236 millions
Sanfilippo John B and Son Inc-3.53%$ -3.531 millions
Brightview Holdings Inc -3.71%$ -3.710 millions
Beyond Meat Inc -6.79%$ -6.790 millions
Vital Farms Inc -7.98%$ -7.980 millions
Smithfield Foods Inc -8.27%$ -8.273 millions
American Vanguard Corporation-9.09%$ -9.091 millions
Ispire Technology Inc-9.25%$ -9.253 millions
Mgp Ingredients Inc -9.60%$ -9.600 millions
Biote Corp -9.64%$ -9.638 millions
Edgewell Personal Care Company-9.88%$ -9.885 millions
Mosaic Co-10.16%$ -10.161 millions
Cvr Partners Lp-10.64%$ -10.637 millions
Mannatech Inc-12.02%$ -12.023 millions
Westrock Coffee Company-15.29%$ -15.294 millions
Natural Health Trends Corp -15.88%$ -15.878 millions
Tofutti Brands Inc -18.76%$ -18.762 millions
Medifast Inc -19.19%$ -19.192 millions
Niagen Bioscience Inc -19.99%$ -19.991 millions
Trulieve Cannabis Corp.-20.12%$ -20.116 millions
Natural Alternatives International Inc-24.80%$ -24.804 millions
The Hain Celestial Group Inc -29.25%$ -29.251 millions
Upexi Inc -62.29%$ -62.292 millions


About Niagen Bioscience Inc Revenue Growth Rates (NAGE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Niagen Bioscience Inc (CIK 1386570).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001386570-26-000056
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Niagen Bioscience Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.